Special Issue

Novel Antinociceptive Agent against Persistent Pain

Message from the Guest Editor

Effective pain therapy is one of society's principal needs. Persistent and neuropathic pain represent a significant clinical problem and, as chronic conditions, can cause distress and seriously affect a patient's quality of life. This condition is often refractory to conventional therapy. Analgesics that are used to treat different persistent pain conditions are usually marked by the onset of several side-effects, and the great majority of patients obtain only partial relief. Therefore, the necessity of new analgesics is clear. Medicinal chemistry is continuously called to face the novel challenges that arise from the steady trickle of scientific breakthroughs to discover new, increasingly safe, and effective drugs. This Special Issue of Molecules welcomes previously unpublished manuscripts covering all aspects of pharmacology and chemistry of antinociceptive drugs, in particular the development of novel pain-relieving molecules which are active against different persistent pain conditions.

Guest Editor

Dr. Laura Micheli Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, 50139 Florence, Italy

Deadline for manuscript submissions

closed (31 August 2021)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/63786

Molecules Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 molecules@mdpi.com

mdpi.com/journal/

molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



molecules



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).